Abstract
In a double-blind, crossover study, 13 fluoxetine-treated patients with obsessive-compulsive disorder were given adjuvant buspirone and placebo for 4 weeks each. There were no significant differences between buspirone and placebo in obsessive-compulsive, depressive, or anxiety symptoms.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Anxiety Disorders / drug therapy
-
Anxiety Disorders / psychology
-
Buspirone / therapeutic use*
-
Depressive Disorder / drug therapy
-
Depressive Disorder / psychology
-
Double-Blind Method
-
Drug Therapy, Combination
-
Female
-
Fluoxetine / therapeutic use*
-
Humans
-
Male
-
Obsessive-Compulsive Disorder / drug therapy*
-
Obsessive-Compulsive Disorder / psychology
-
Placebos
Substances
-
Placebos
-
Fluoxetine
-
Buspirone